Mupirocin


Full Generic Medicine Info
Dosage/Direction for Use

Nasal
Eradication of nasal colonisation with Staphylococci aureus
Adult: As 2% nasal ointment: Apply into each nostril 2-3 times daily for 5-7 days.
Child: Same as adult dose.
Elderly: Same as adult dose.

Topical/Cutaneous
Bacterial skin infections
Adult: As 2% ointment: Apply to affected area 2-3 times daily for up to 10 days according to individual response.
Child: Same as adult dose.
Elderly: Same as adult dose.

Topical/Cutaneous
Impetigo
Adult: As 2% ointment: Apply to affected area 2-3 times daily for up to 10 days according to individual response.
Child: Same as adult dose.
Elderly: Same as adult dose.

Topical/Cutaneous
Secondary skin infections
Adult: As 2% cream: Apply to affected area tid for up to 10 days according to individual response; re-evaluate after 3-5 days if no clinical response.
Child: ≥1 year Same as adult dose.
Elderly: Same as adult dose.
Contraindications
Hypersensitivity.
Special Precautions
Patient with extensive burns or open wounds. Not indicated for treatment of pressure sores. Renal impairment. Children and elderly. Pregnancy and lactation. Patient Counselling Avoid contact with eyes and mucous membranes.
Adverse Reactions
Significant: Fungal or bacterial superinfection, cutaneous sensitisation reaction or severe local irritation, systemic allergic reactions (e.g. angioedema, urticaria, generalised rash). Eye disorders: Burning and tearing of eyes (nasal ointment). Gastrointestinal disorders: Nausea, dry mouth (nasal ointment). General disorders and administration site conditions: Application site reactions (e.g. localised burning, stinging or tingling sensation, localised pain and swelling), irritation, soreness. Nervous system disorders: Headache, dysgeusia (nasal ointment). Respiratory, thoracic and mediastinal disorders: Rhinitis, sinusitis, respiratory congestion, pharyngitis, cough, post nasal drip, nasal mucosa reactions. Skin and subcutaneous tissue disorders: Pruritus, erythema, skin dryness, rash, contact dermatitis.
Action
Mupirocin, an antibiotic produced by fermentation of Pseudomonas fluorescens, inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl transfer-ribonucleic acid (tRNA) synthetase. It has bacteriostatic effects at minimum inhibitory concentrations and bactericidal effects at higher concentrations.
Absorption: Minimally absorbed systemically through intact skin.
Distribution: Plasma protein binding: >97%.
Metabolism: Rapidly metabolised to its inactive metabolite, monic acid.
Excretion: Via urine (as inactive monic acid metabolite). Elimination half-life: 17-36 minutes.
Storage
Nasal: Store below 25°C. Do not refrigerate or freeze. Topical/Cutaneous: Store below 25°C. Do not refrigerate or freeze.
CIMS Class
ATC Classification
D06AX09 - mupirocin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
R01AX06 - mupirocin ; Belongs to the class of other nasal preparations for topical use.
Disclaimer: This information is independently developed by CIMS based on mupirocin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in